A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit
Phase: PHASE2
Conditions: COVID-19
Sponsor: Grifols Therapeutics LLC

Official Title: 
A Multicenter, Randomized, Open-label  Parallel Group  Pilot Study to 
Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG)
Plus Standard Medical Treatment  (SMT) Versus SMT Alone in Subjects With  
COVID-19 Requiring Admission to the Intensive Care Unit
NCT Number: 
NCT04480424
Document Date: 
Protocol Version 4.0: 19 July 2021